Drug
Romidepsin clinical trials
Also written FK228 and FR901228.
- studies test it
- 73
- open now
- 1
- in phase 3
- 0
- first study started
- 1997
Keep track of what changes. Save the romidepsin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Istodax
- 40
Combined with it in one product
Studies by the year they started
73 studies that test it; most in 2004 (9)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 4 |
| 2003 | 4 |
| 2004 | 9 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 8 |
| 2014 | 6 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 43
- Phase 2
- 43
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 61
National Cancer Institute (NCI) (23) · Celgene (11) · Memorial Sloan Kettering Cancer Center (4) · M.D. Anderson Cancer Center (2) · Fondazione Italiana Linfomi - ETS (2) · Northwestern University (2) · Ohio State University Comprehensive Cancer Center (2) · Columbia University (2)
Often tested with
Tested in the same studies.
Lenalidomide (5) · Dexamethasone (4) · Gemcitabine (4) · Bortezomib (3) · Cc-486 (2) · Carfilzomib (2) · Doxorubicin (2) · Pralatrexate (2)
Studies
Open first, then newest update. How each study uses romidepsin is read from its arms, and is right about nine times in ten.
Testing it · 73
- Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology AgentsRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT06963346Written as Romidepsin
- Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell MalignanciesCompletedPhase 1National Cancer Institute (NCI)NCT04447027Written as Romidepsin
- Study of Pembrolizumab (MK-3475) in Combination With RomidepsinActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT03278782Written as Romidepsin
- Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid MalignanciesTerminatedPhase 1/2Jennifer AmengualNCT01947140Written as Romidepsin
- Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell LymphomasCompletedPhase 1/2Fondazione Italiana Linfomi - ETSNCT02223208Written as Ro-CHOEP-21 (PHASE I)
- Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell LymphomaCompletedPhase 2Northwestern UniversityNCT02232516Written as romidepsin
- Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)TerminatedPhase 1/2University of Michigan Rogel Cancer CenterNCT03547700Written as Romidepsin
- Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell LymphomasCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT02783625Written as Romidepsin
- Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell LymphomaCompletedPhase 1Canadian Cancer Trials GroupNCT01846390Written as Romidepsin
- Romidepsin Maintenance After Allogeneic Stem Cell TransplantationCompletedPhase 1Ohio State University Comprehensive Cancer CenterNCT02512497Written as Romidepsin
- Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast CancerTerminatedPhase 1/2Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT01938833Written as Romidepsin
- Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ARTCompletedPhase 2Aarhus University HospitalNCT03041012Written as Romidepsin
- A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell LymphomaCompletedPhase 1Fox Chase Cancer CenterNCT02616965Written as Romidepsin
- Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedPhase 1National Cancer Institute (NCI)NCT01638533Written as Romidepsin
- Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell LymphomasCompletedPhase 1Walter HanelNCT04774068Written as Romidepsin
- Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and MyelomaCompletedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT01755975Written as Romidepsin
- Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid MalignanciesTerminatedPhase 1/2Columbia UniversityNCT01998035Written as RomiDEPsin 10 MG/M2
- Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected IndividualsCompletedPhase 1IrsiCaixaNCT02616874Written as Romidepsin
- Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell LymphomasCompletedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT02341014Written as Romidepsin
- FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung CancerCompletedPhase 2National Cancer Institute (NCI)NCT00020202Written as FR901228
See all 73 studies that test romidepsin →
Given in every arm · 9 — romidepsin is usual care beside what is tested
- Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCLRecruitingPhase 2University of VirginiaNCT04747236Written as Romidepsin
- A Study of Enhancing Response to MK-3475 in Advanced Colorectal CancerCompletedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT02512172Written as Romidepsin
- Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Active, not recruitingPhase 1/2Priyanka SharmaNCT02393794Written as Romidepsin
- Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic CancerCompletedPhase 1/2GWT-TUD GmbHNCT04257448Written as Romidepsin
- Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerTerminatedPhase 1Mayo ClinicNCT03432741Written as Romidepsin
- Romidepsin Plus 3BNC117 Phase 2a StudyCompletedPhase 2Rockefeller UniversityNCT02850016Written as Romidepsin
- Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCLWithdrawnPhase 3Jennifer AmengualNCT03355768Written as Romidepsin
- Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 ReservoirCompletedPhase 1/2Bionor Immuno ASNCT02092116Written as Romidepsin
- Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative DisordersCompletedPhase 1National Cancer Institute (NCI)NCT00114257Written as romidepsin
As the comparator · 3 — what is tested is compared with romidepsin
- Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell LymphomaCompletedPhase 3CelgeneNCT03703375Written as Romidepsin
- Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITLCompletedPhase 3The Lymphoma Academic Research OrganisationNCT03593018Written as Romidepsin
- Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell LymphomaCompletedPhase 3Millennium Pharmaceuticals, Inc.NCT01482962Written as Romidepsin
Codes
What other systems call romidepsin · ClinicalTrials.gg INT003787
- MeSH (NLM) C087123romidepsinOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C087123 | romidepsin | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.